Skip to content

Application of the Apsara Thermal Wand System

TP-1013 Pilot 1: Application of the Apsara Thermal Wand System

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00662389
Enrollment
4
Registered
2008-04-21
Start date
2008-04-30
Completion date
2009-03-31
Last updated
2009-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tightening of Skin Laxity

Keywords

skin laxity, wrinkles, rhytids

Brief summary

The purpose of this feasibility study is to gain an initial assessment of the acute safety and performance of the Apsara Thermal Wand System in human facial tissue.

Interventions

DEVICEApsara Thermal Wand System

Single radiofrequency cycle to dermal tissue

Sponsors

Apsara Medical Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Nonsmoker * Glogau class 1-3 * Previously chosen to undergo facelift

Exclusion criteria

* Pregnant, nursing * Implanted electro-mechanical device * Allergy to anesthesia or device metals * Collagen vascular disease * History of keloid or hypertrophic scar formation * Uncontrolled diabetes * Long term steroid or other immunologic inhibitor use * Previous treatment to target area * Does not consent to study * Does not consent to photography or histological evaluation

Design outcomes

Primary

MeasureTime frameDescription
Serious Adverse EventsImmediateNumber of Serious Adverse Events

Countries

United States

Participant flow

Participants by arm

ArmCount
A--Thermal Wand Application4
Total4

Baseline characteristics

CharacteristicA--Thermal Wand Application
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
1 Participants
Age, Categorical
Between 18 and 65 years
3 Participants
Age Continuous61.7 years
STANDARD_DEVIATION 3.6
Region of Enrollment
United States
4 participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
0 Participants

Outcome results

Primary

Serious Adverse Events

Number of Serious Adverse Events

Time frame: Immediate

ArmMeasureValue (NUMBER)
A--Thermal Wand ApplicationSerious Adverse Events0 Number of Serious Adverse Events

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026